Pharmacoeconomic Evaluation of Dapagliflozin Combined with Conventional Treatment of Heart Failure

OBJECTIVE To evaluate the cost-effectiveness of dapagliflozin plus conventional therapy in the treatment of heart failure.METHODS On the basis of the clinical trial of dapagliflozin,the Markov model was established to compare the cost-effectiveness of conventional therapeutic group and dapagliflozin group (dapagliflozin plus conventional group) in heart failure patients.Quality-adjusted life years (QALYs) were employed as the indicator of health outcomes.With a willingness-to-pay threshold of one time of the Chinese per-capita gross domestic product,the long-term effects and costs of two treatment groups were simulated and sensitivity analyses of cost,utlity and discount were performed for testing the stability of results.RESULTS The incremental cost-effectiveness ratio of the dapagliflozin group to conventional group was 8 821.32 yuan/QALY.It was less than willingness-to-pay and the incremental cost was acceptable.The probabilistic sensitivity analysis showed that the probability of cost-utility in the dapagliflozin group was 87.4%.CONCLUSION Compared with conventional therapy,dapagliflozin plus conventional therapy has a better economic in patients with heart failure.